Navigation Links
SWOG names 5 cancer researchers outstanding Young Investigators
Date:9/8/2010

ANN ARBOR, Mich. The Southwest Oncology Group, or SWOG, one of the nation's largest cancer clinical trials networks, has selected five talented researchers who are early in their careers for its 2010 Young Investigator Training Course (YITC). These five will attend a three-day workshop September 13 15 in Seattle, WA for intensive training in how to design and conduct cancer clinical trials.

To date this nationally acclaimed program has provided intensive mentorship and career support to 56 investigators. With detailed instruction in protocol development, trial management, and statistical analysis, the course is designed to build a cohort of trained clinical trial researchers with a thorough understanding of Group procedures and the ability to efficiently plan and execute high-priority studies, which in some cases might enroll thousands of patients at hundreds of treatment sites.

Each Young Investigator presents a research proposal as part of the application process, and those proposals are closely reviewed and refined during the workshop. Many of the proposals advanced in previous workshops have since been launched as studies with National Cancer Institute funding.

Costs of the Young Investigator program are paid for with a gift from The Hope Foundation (thehopefoundation.org), a philanthropic arm of the Southwest Oncology Group that raises funds for educational and research efforts.

Below are the names of the 2010 SWOG Young Investigators and descriptions of their proposals.

Sikander Ailawadhi, assistant professor of medicine, University of Southern California:

Ailawadhi has proposed a clinical trial to test the effect of a three-drug combination of carfilzomib, cyclophosphamide, and dexamethasone in multiple myeloma (MM) patients who have disease relapse outside the bone marrow, known as extramedullary relapse. "This is an increasingly identified condition which carries a very poor prognosis," says Ailawadhi, "but there are no specific therapeutic approaches for it yet."

Myeloma cells typically do not grow outside the bone marrow, so developing extramedullary relapsed disease may be a sign of change in MM biology. This proposed study would also explore whether identifying gene expression signatures in these patients can improve our understanding of the molecular mechanisms involved in progression of this disease from the bone marrow into extramedullary sites.

Heather Greenlee, N.D., Ph.D., assistant professor of epidemiology and medical oncology, Columbia University:

With doctoral training in cancer epidemiology and clinical training as a naturopathic physician, Greenlee researches the effects of complementary and alternative medicine therapies on treatment toxicities, patient quality of life, cancer recurrence, and survival.

She has proposed a study among breast and colorectal cancer survivors to assess the feasibility of a weight loss intervention using the Curves weight loss program, which combines circuit-based exercise with a calorie-reduced diet high in fruits and vegetables and low in fat. This study concept is now under review at the National Cancer Institute as proposed SWOG trial S1008.

Kevin Kalinsky, M.D., assistant professor of medicine, Columbia University:

Kalinsky has proposed a phase I study of a regimen that combines antibodies to human epidermal growth factor receptor 3 (HER3) and insulin-like growth factor 1 receptor (IGF-1R) with trastuzumab (Herceptin) in patients with advanced solid tumors.

Trastuzumab can help control breast cancer in which the HER2 gene is amplified (multiple copies of the gene are made) or HER2 itself is overexpressed. It does this by interfering with the HER2 receptor, but many patients become resistant to the drug's effects. Recent research suggests that HER2, HER3, and IGF-1R work together in creating this resistance in some breast cancer cells. Kalinsky's proposed study would target these latter two receptors directly in an attempt to make tumor cells more sensitive to trastuzumab.

Tina (Tianhong) Li, M.D., Ph.D., assistant professor of medicine, UC Davis Cancer Center:

Li proposes a phase II study pitting the drugs crizotinib and pemetrexed against crizotinib alone in patients whose non-small cell lung cancer (NSCLC) hasn't responded to platinum-based therapy and harbors a particular genetic abnormality known as the EML4-ALK fusion oncogene.

Current data suggest that the frequency of several variants of this EML4-ALK fusion oncogene, which is only 4-6% among all NSCLC patients, is particularly high in younger patients and in non-smokers or light smokers. The study would screen this subset of NSCLC patients for the genetic marker to determine trial eligibility.

SWOG's Lung Committee approved this proposal for further development during the spring 2010 Group Meeting.

Margarett Shnorhavorian, M.D., M.P.H., assistant professor of urology, University of Washington:

Shnorhavorian is the first investigator to participate in the course as part of a recent partnership between SWOG and the Children's Oncology Group (COG) that opens the YITC to researchers honored with COG's Aflac Young Investigator Award in Adolescent and Young Adult Oncology, which Shnorhavorian received in 2009.

She has proposed a pilot study of infertility and gonadal dysfunction in male survivors of adolescent and young adult (AYA) osteosarcomas who were treated with cisplatin chemotherapy. Cisplatin and other similar drugs have cumulative dose ranges above which most patients will be rendered infertile, but Shnorhavorian says population-based studies are needed to describe the prevalence of these effects in survivors of AYA malignancies.


'/>"/>

Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. ASTRO names radiologist, ABR president Societys 2010 Honorary Member
2. Jackson Surgical Assistants Names Dr. Sidney Funk as Medical Director
3. More Big Names Line Up To Support Global Hearing Loss Awareness Initiative
4. San Antonio Business Journal Names BMI of Texas One of the Best Places to Work in San Antonio
5. National Leadership Program Names New Class of Fellows
6. Vietnamese Student Named UMass Boston JFK Award Winner
7. Leveragepoint Names Jay Manson Vice President Sales For Online Value Management Tools
8. CBCA Names Tim Reed as Vice President, Human Resources
9. Leading Industry Analyst Firm Names ActiveBase "Cool Vendor"
10. Locum Tenens Organization Names CompHealth Executive to Board of Directors
11. Outside Magazine Names LeBootCamp as One of America's Best Places to Work in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER ... ensure lab personnel have a basic understanding of the techniques they use so ... understanding will help them reduce waste and rework to create a leaner overall ...
(Date:2/9/2016)... Santa Rosa, California (PRWEB) , ... February 09, 2016 , ... ... been rated one of the highest preliminary data vendors in the latest KLAS report, ... 15 years, i2i has led the developing market for population health management (PHM). ...
(Date:2/8/2016)... Bethlehem, PA (PRWEB) , ... February 08, 2016 ... ... announce expanded authorization with BASF Human Nutrition into the Food & Beverage ... BSI has been BASF’s channel partner throughout Canada and USA geographies east ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... packer for pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, ... product manufacturers step up to semi-automatic or fully-automatic case packing with a small ...
(Date:2/8/2016)... Venice, FL (PRWEB) , ... February 08, 2016 ... ... their new community enrichment program serving the greater Venice, FL area, has initiated ... died tragically in a car accident just four days after Christmas. To support ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
(Date:2/9/2016)... YORK, Pa., Feb. 9, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced its financial results for ... 2015). ... Revenue for the ... million in the same period last year.  Cash receipts from customers ...
(Date:2/9/2016)... Feb. 9, 2016  Jazz Pharmaceuticals plc (Nasdaq: ... 2015 fourth quarter and full year financial results on ... financial markets.  Company management will host a live audio ... p.m. GMT to discuss fourth quarter and full year ... update and guidance for 2016 financial results. ...
Breaking Medicine Technology: